Ray Boyapati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ray Boyapati has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Gwo-Tzer Ho
School of InfecDon and Immunity, University of Glasgow, Glasgow, United Kingdom
8 shared publications Jack Satsangi
Translational Gastroenterology Unit, Nuffield Department of Medicine, Experimental Medicine Division, University of Oxford, John Radcliffe Hospital, Oxford, UK
8 shared publicationsRhys Vaughan
Department of Gastroenterology and Liver Transplant Unit, Austin Hospital, Heidelberg, Victoria, Australia; Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
4 shared publicationsMarcus Robertson
Department of Gastroenterology and Liver Transplant Unit, Austin Hospital, Heidelberg, Victoria, Australia
3 shared publications- Avik Majumdar
Victorian Liver Transplant Unit, Austin Health, Melbourne, Australia
2 shared publications James Wei
Department of Gastroenterology and Liver Transplant Unit, Austin Hospital, Heidelberg, Victoria, Australia
2 shared publications
Latest Publications
- Open Access
Machine learning approach to dissect the clinical heterogeneity of IBD-associated fatigue
Extreme fatigue is a clinical symptom that affects >50% of individuals with Inflammatory Bowel Disease (IBD), with a similar prevalence across many common immune-mediated inflammatory diseases (IMIDs). Despite its ubiquity, human scientific studies have yet to explain the mechanistic basis of this pervasive and complex symptom. One fundamental reason for this, is our inability to account for the clinical heterogeneity of fatigue with its multifactorial nature. We present the conceptual machine learning (ML) framework to dissect the complex nature of fatigue using one of the largest prospectively captured, real-world patient-reported outcome (PROs) on wellbeing from three contemporaneous cohorts (2020-present), totalling 2,970 responses from 2,290 participants across the UK and internationally, including non-IBD controls with 100 lines of clinical metadata. We systematically defined the (1) threshold of fatigue as our primary outcome (≥10/14 fatigue days) to build our ML approach, (2) utilised routinely available clinical data that can be used at a population-level analysis, (3) employed seven different ML methods with external validation in 3 different cohorts in UK, Spain and Australia (n=252), (4) employed Shapley Additive Explanations (SHAP) analysis to break down the clinical heterogeneity to allow the examination of clinical predictive factors at an individual level; and finally (5), investigate whether there are distinct clusters of fatigue patients. We found that ML models performed comparably (AUC/C-index ∼0.7) on external validation with SHAP analysis showing interpretable, individualised fatigue drivers and five distinct fatigue phenotypes, including a subgroup of young males with significantly lower fatigue burden. Our data therefore provides the ML ‘roadmap’ to predict and deconstruct fatigue in IBD and potentially also more widely in IMIDs, enabling patient-level dissection beyond symptom-based classification with the ability to integrate deep molecular data. This is a step towards future clinical-scientific AI models with the immediate clinical application to stratify patients to human experimental studies to better understand the dominant mechanisms that drive fatigue at an individual level.
Open AccessMachine learning approach to dissect the clinical heterogeneity of IBD-associated fatigue
Extreme fatigue is a clinical symptom that affects >50% of individuals with Inflammatory Bowel Disease (IBD), with a similar prevalence across many common immune-mediated inflammatory diseases (IMIDs). Despite its ubiquity, human scientific studies have yet to explain the mechanistic basis of this pervasive and complex symptom. One fundamental reason for this, is our inability to account for the clinical heterogeneity of fatigue with its multifactorial nature. We present the conceptual machine learning (ML) framework to dissect the complex nature of fatigue using one of the largest prospectively captured, real-world patient-reported outcome (PROs) on wellbeing from three contemporaneous cohorts (2020-present), totalling 2,970 responses from 2,290 participants across the UK and internationally, including non-IBD controls with 100 lines of clinical metadata. We systematically defined the (1) threshold of fatigue as our primary outcome (≥10/14 fatigue days) to build our ML approach, (2) utilised routinely available clinical data that can be used at a population-level analysis, (3) employed seven different ML methods with external validation in 3 different cohorts in UK, Spain and Australia (n=252), (4) employed Shapley Additive Explanations (SHAP) analysis to break down the clinical heterogeneity to allow the examination of clinical predictive factors at an individual level; and finally (5), investigate whether there are distinct clusters of fatigue patients. We found that ML models performed comparably (AUC/C-index ∼0.7) on external validation with SHAP analysis showing interpretable, individualised fatigue drivers and five distinct fatigue phenotypes, including a subgroup of young males with significantly lower fatigue burden. Our data therefore provides the ML ‘roadmap’ to predict and deconstruct fatigue in IBD and potentially also more widely in IMIDs, enabling patient-level dissection beyond symptom-based classification with the ability to integrate deep molecular data. This is a step towards future clinical-scientific AI models with the immediate clinical application to stratify patients to human experimental studies to better understand the dominant mechanisms that drive fatigue at an individual level.
- Open Access
Bacillus Subtilis (BG01-4TM) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial
Background: Functional gastrointestinal disorders (FGIDs) are common, difficult-to-manage conditions. Probiotics are emerging as a dietary component that influence gastrointestinal (GI) health. We conducted a double-blinded randomised controlled trial of a proprietary strain of deactivated Bacillus subtilis (BG01-4™) high in branched-chain fatty acids (BCFA) to treat self-reported FGID. Methods: Participants (n = 67) completed a four-week intervention of BG01-4™ (n = 34) or placebo (n = 33). The Gastrointestinal Symptom Rating Scale (GSRS) served as the outcome measure, collected prior to, at two weeks, and at four weeks after completion of the intervention. Results: At four weeks, one of three primary outcomes, constipation in the experimental group, was improved by 33% compared to placebo (15%); both other primary outcomes, Total GSRS and diarrhoea, were significantly improved in both the experimental and placebo groups (32%/26% and 20%/22%, respectively). The pre-planned secondary outcome, indigestion, was improved at four weeks (32%) but compared to the placebo (21%) was not significant (p = 0.079). Exploratory analysis, however, revealed that clusters for constipation (18% improvement, p < 0.001), indigestion (11% improvement, p = 0.04), and dyspepsia (10% improvement, p = 0.04) were significantly improved in the intervention group compared to the placebo. Conclusions: These initial findings suggest that in people with self-reported FGID, BG01-4™ improves specific symptoms of constipation and related GI dysfunction. Longer-term confirmatory studies for this intervention are warranted. Trial registration: This study was registered prospectively (25 October 2021) at the Australian New Zealand Clinical Trials Registry (ACTRN12621001441808p).
Open AccessBacillus Subtilis (BG01-4TM) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial
Background: Functional gastrointestinal disorders (FGIDs) are common, difficult-to-manage conditions. Probiotics are emerging as a dietary component that influence gastrointestinal (GI) health. We conducted a double-blinded randomised controlled trial of a proprietary strain of deactivated Bacillus subtilis (BG01-4™) high in branched-chain fatty acids (BCFA) to treat self-reported FGID. Methods: Participants (n = 67) completed a four-week intervention of BG01-4™ (n = 34) or placebo (n = 33). The Gastrointestinal Symptom Rating Scale (GSRS) served as the outcome measure, collected prior to, at two weeks, and at four weeks after completion of the intervention. Results: At four weeks, one of three primary outcomes, constipation in the experimental group, was improved by 33% compared to placebo (15%); both other primary outcomes, Total GSRS and diarrhoea, were significantly improved in both the experimental and placebo groups (32%/26% and 20%/22%, respectively). The pre-planned secondary outcome, indigestion, was improved at four weeks (32%) but compared to the placebo (21%) was not significant (p = 0.079). Exploratory analysis, however, revealed that clusters for constipation (18% improvement, p < 0.001), indigestion (11% improvement, p = 0.04), and dyspepsia (10% improvement, p = 0.04) were significantly improved in the intervention group compared to the placebo. Conclusions: These initial findings suggest that in people with self-reported FGID, BG01-4™ improves specific symptoms of constipation and related GI dysfunction. Longer-term confirmatory studies for this intervention are warranted. Trial registration: This study was registered prospectively (25 October 2021) at the Australian New Zealand Clinical Trials Registry (ACTRN12621001441808p).
- Open Access
- 28 January 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 54
Precision medicine in inflammatory bowel disease: concept, progress and challenges
Crohn’s disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from “reactive” management driven by disease complications to “proactive” care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach.
- 28 January 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 54
Open AccessPrecision medicine in inflammatory bowel disease: concept, progress and challenges
Crohn’s disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from “reactive” management driven by disease complications to “proactive” care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S90
Mitochondrial DNA is a Damage-Associated Molecular Pattern (DAMP) Released during Active IBD Promoting TLR9-Mediated Inflammation
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S90
Mitochondrial DNA is a Damage-Associated Molecular Pattern (DAMP) Released during Active IBD Promoting TLR9-Mediated Inflammation
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S962-S963
MDR1-Deficiency Unmasks Mitochondrial Dysfunction as a Pathogenic Mechanism in IBD
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S962-S963
MDR1-Deficiency Unmasks Mitochondrial Dysfunction as a Pathogenic Mechanism in IBD
- Open Access
- 2 February 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (2)
Withdrawal of drug therapy for patients with quiescent Crohn's disease
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective of this review is to assess the feasibility and safety of discontinuing immunosuppressant or biologic drugs, administered alone or in combination, in patients with quiescent CD.
- 2 February 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (2)
Open AccessWithdrawal of drug therapy for patients with quiescent Crohn's disease
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective of this review is to assess the feasibility and safety of discontinuing immunosuppressant or biologic drugs, administered alone or in combination, in patients with quiescent CD.
- 1 December 2016
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 111 (12) , 1796-1805
Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases
There is an unmet need for novel blood-based biomarkers that offer timely and accurate diagnostic and prognostic testing in inflammatory bowel diseases (IBD). We aimed to investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD. A total of 171 patients (n=96 IBD, n=75 non-IBD) were prospectively recruited. A multi-biomarker model was derived using multivariable logistic regression analysis. Cox proportional hazards model was derived to assess the contribution of each variable to disease outcomes. SC correlated strongly with current biomarkers, including fecal calprotectin (FC) (n=50, ρ=0.50, P=1.6 × 10−4). SC was the strongest individual predictor of IBD diagnosis (odds ratio (OR): 9.37 (95% confidence interval (CI): 2.82–34.68), P=4.00 × 10−4) compared with other markers (C-reactive protein (CRP): OR 8.52 (95% CI: 2.75–28.63), P=2.80 × 10−4); albumin: OR 6.12 (95% CI: 1.82–22.16), P=0.004). In a subset of 50 patients with paired SC and FC, the area under receiver operating characteristic discriminating IBD from controls was better for FC than for SC (0.99, (95% CI 0.87–1.00) and 0.87 (95% CI:0.78–0.97), respectively; P=0.01). At follow-up (median 342 days; interquartile range: 88–563), SC predicted treatment escalation and/or surgery in IBD (hazard ratio (HR) 2.7, 95% CI: 1.1–4.9), in particular Crohn’s disease (CD) (HR 4.2, 95% CI 1.2–15.3). A model incorporating SC and either CRP or albumin has a positive likelihood ratio of 24.14 for IBD. At 1 year, our prognostic model can predict treatment escalation in IBD in 65% of cases (95% CI: 43–79%) and 80% (95% CI: 31–94%) in CD if ≥2 blood marker criteria are met. A diagnostic and prognostic model that combines SC and other blood-based biomarkers accurately predicts the inflammatory burden in IBD and has the potential to predict disease and its outcomes. Our data warrant further detailed exploration and validation in large multicenter cohorts.
- 1 December 2016
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 111 (12) , 1796-1805
Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases
There is an unmet need for novel blood-based biomarkers that offer timely and accurate diagnostic and prognostic testing in inflammatory bowel diseases (IBD). We aimed to investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD. A total of 171 patients (n=96 IBD, n=75 non-IBD) were prospectively recruited. A multi-biomarker model was derived using multivariable logistic regression analysis. Cox proportional hazards model was derived to assess the contribution of each variable to disease outcomes. SC correlated strongly with current biomarkers, including fecal calprotectin (FC) (n=50, ρ=0.50, P=1.6 × 10−4). SC was the strongest individual predictor of IBD diagnosis (odds ratio (OR): 9.37 (95% confidence interval (CI): 2.82–34.68), P=4.00 × 10−4) compared with other markers (C-reactive protein (CRP): OR 8.52 (95% CI: 2.75–28.63), P=2.80 × 10−4); albumin: OR 6.12 (95% CI: 1.82–22.16), P=0.004). In a subset of 50 patients with paired SC and FC, the area under receiver operating characteristic discriminating IBD from controls was better for FC than for SC (0.99, (95% CI 0.87–1.00) and 0.87 (95% CI:0.78–0.97), respectively; P=0.01). At follow-up (median 342 days; interquartile range: 88–563), SC predicted treatment escalation and/or surgery in IBD (hazard ratio (HR) 2.7, 95% CI: 1.1–4.9), in particular Crohn’s disease (CD) (HR 4.2, 95% CI 1.2–15.3). A model incorporating SC and either CRP or albumin has a positive likelihood ratio of 24.14 for IBD. At 1 year, our prognostic model can predict treatment escalation in IBD in 65% of cases (95% CI: 43–79%) and 80% (95% CI: 31–94%) in CD if ≥2 blood marker criteria are met. A diagnostic and prognostic model that combines SC and other blood-based biomarkers accurately predicts the inflammatory burden in IBD and has the potential to predict disease and its outcomes. Our data warrant further detailed exploration and validation in large multicenter cohorts.
- 1 December 2016
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 111 (12) , 1682-1690
Biomarkers in Search of Precision Medicine in IBD
The completion of the human genome project in 2003 represented a major scientific landmark, ushering in a new era with hopes and expectations of fresh insights into disease mechanisms and treatments. In inflammatory bowel disease (IBD), many important discoveries soon followed, notably the identification of >200 genetic susceptibility loci and characterization of the gut microbiome. As “big data”, driven by advances in technology, becomes increasingly available and affordable, individuals with IBD and clinicians alike yearn for tangible outcomes from the promise of “precision medicine”—precise diagnosis, monitoring, and treatment. Here, we provide a commentary on the prospects and challenges of precision medicine and biomarkers in IBD. We focus on the three key areas where precision IBD will have the most impact: (1) disease susceptibility, activity, and behavior; (2) prediction of drug response and adverse effects; and (3) identification of subphenotypic mechanisms to facilitate drug discovery and selection of new treatments in IBD.
- 1 December 2016
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 111 (12) , 1682-1690
Biomarkers in Search of Precision Medicine in IBD
The completion of the human genome project in 2003 represented a major scientific landmark, ushering in a new era with hopes and expectations of fresh insights into disease mechanisms and treatments. In inflammatory bowel disease (IBD), many important discoveries soon followed, notably the identification of >200 genetic susceptibility loci and characterization of the gut microbiome. As “big data”, driven by advances in technology, becomes increasingly available and affordable, individuals with IBD and clinicians alike yearn for tangible outcomes from the promise of “precision medicine”—precise diagnosis, monitoring, and treatment. Here, we provide a commentary on the prospects and challenges of precision medicine and biomarkers in IBD. We focus on the three key areas where precision IBD will have the most impact: (1) disease susceptibility, activity, and behavior; (2) prediction of drug response and adverse effects; and (3) identification of subphenotypic mechanisms to facilitate drug discovery and selection of new treatments in IBD.
- 1 June 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (6) , 1151-1160
Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems
- 1 June 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (6) , 1151-1160
Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems
- 1 May 2016
- Published by Elsevier in Mucosal Immunology
- Vol. 9 (3) , 567-582
Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications
- 1 May 2016
- Published by Elsevier in Mucosal Immunology
- Vol. 9 (3) , 567-582
Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications